LY-2584702 hydrochloride NEW
| Price | $1520 | $1980 | $2500 |
| Package | 25mg | 50mg | 100mg |
| Min. Order: | |
| Supply Ability: | 10g |
| Update Time: | 2025-10-27 |
Product Details
| Product Name: LY-2584702 hydrochloride | CAS No.: 1082948-81-9 |
| Supply Ability: 10g | Release date: 2025/10/27 |
Product Introduction
Bioactivity
| Name | LY-2584702 hydrochloride |
| Description | Ly-2584702 hydrochloride is a p70S6K selective ATP competitive inhibitor with IC50 of 4 nM.In the S6K1 enzyme assay, the IC50 of LY-2584702 was 2 nM. |
| In vitro | LY-2584702 has some activity against the S6K-related kinases MSK2 and RSK at high concentrations (enzyme assay IC50=58-176 nM).?LY-2584702 inhibits S6K activity in EOMA cells, as determined by the phosphorylation of its downstream effector S6, in a dose-dependent manner[2].?Proliferation of A549 is significantly inhibited by LY-2584702 ?treating over 24 h at 0.1 μM (P<0.05);?and the trend of decline is more conspicuous with longer treatment and/or with the increased drug concentration (all P<0.05).?Similar results are also observed in SK-MES-1, although the obvious inhibition is led by LY-2584702 at 0.6 μM (P<0.05), much higher than that of A549[3].LY-2584702 ?inhibits phosphorylation of the S6 ribosomal protein (pS6) in HCT116 colon cancer cells with an IC50 of 0.1-0.24 μM[1].?In S6K1 enzyme assay, the IC50 of LY-2584702 ?is 2 nM.?For pS6 inhibition in cells, the IC50=100 nM. |
| In vivo | LY-2584702 significantly inhibits tumor growth as a single agent in U87MG glioblastoma and HCT116 colon carcinoma xenograft models at doses of 2.5 mg/kg and 12.5 mg/kg twice daily (BID), achieving noteworthy tumor growth reduction at threshold minimum effective dose 50% (TMED50) of 2.3 mg/kg and TMED90 of 10 mg/kg in the HCT116 model[1]. In vivo studies involving EOMA cells expressing shAkt3 implanted in nu/nu mice show that, when treated with LY-2584702 or Rapamycin for 14 days, LY-2584702 nearly matches Rapamycin in inhibiting S6 phosphorylation, highlighting its potential mechanism of action against tumors. Additionally, while LY-2584702 does not significantly change the growth of pLKO tumors, it considerably reduces tumor growth in shAkt3 expressing tumors after a 14-day treatment period, pointing to the enhanced tumor growth in the absence of Akt3[2]. |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
| Keywords | S6Kinase | S6K1 | S6 Kinase | p70S6K | LY-2584702 Hydrochloride | LY2584702 Hydrochloride | LY2584702 hydrochloride | LY 2584702 hydrochloride | LY 2584702 Hydrochloride |
| Inhibitors Related | CHIR-98014 | Quercitrin | H-89 dihydrochloride | AD80 | BI-D1870 | Bimiralisib | MBM-55S | A-443654 | Prexasertib dihydrochloride | FMK | CYC-116 | Sodium salicylate |
Company Profile Introduction
TargetMol Chemicals Inc. is headquartered in Boston, MA, and specializes in products and services that serve the research needs of chemical and biological scientists worldwide. With a client base in 40+ countries, TargetMol has evolved into one of the biggest global research suppliers for compound libraries and small molecule compounds.
170+ Compound Libraries， 10000+ Noval Small Molecucles，16000+ Nature Compounds
TargetMol diligently updates and offers over 170 types of compound libraries and a wide range of high-quality research chemicals, including inhibitors, activators, natural products, peptides, antibodies , and novel life-science kits for laboratory and scientific use. In addition, our lab allows us to conduct CADD (computer-aided drug design) and chemical synthesis to meet the customization needs of our clients.
You may like
Recommended supplier
| Product name | Price | Suppliers | Update time | |
|---|---|---|---|---|
| $116.00/5mg |
VIP6Y
|
TargetMol Chemicals Inc.
|
2025-10-26 | |
| $1.10/1g |
VIP5Y
|
Shaanxi Dideu Medichem Co. Ltd
|
2021-05-06 |
United States- Since: 2011-01-07
- Address: 36 Washington Street, Wellesley Hill, Massachusetts, USA
INQUIRY